Literature DB >> 3496062

The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs.

J L Carson, B L Strom, M L Morse, S L West, K A Soper, P D Stolley, J K Jones.   

Abstract

To assess the relative rate or upper gastrointestinal (UGI) tract bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs), we performed a retrospective cohort study using 1980 billing data from all Medicaid patients in the states of Michigan and Minnesota. The rate of UGI tract bleeding in the 30 days following each drug exposure was examined in the 88,044 patients dispensed only one of seven NSAIDs. The rate of UGI tract bleeding differed significantly among users of these drugs. Stratification and logistic regression were used to adjust for multiple potential confounding factors, without substantive changes in the results. An alcohol-drug interaction was found. Sulindac users had the highest rate of UGI tract bleeding, and it was the only drug statistically different from ibuprofen. When the average daily dose of sulindac received was divided by the maximum recommended daily dose, it was notably higher than those for other drugs. Repeated analyses using data from 1982 confirmed these results. We conclude that there are significant and consistent differences in the incidence of UGI tract bleeding associated with the use of NSAIDs in this population.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3496062

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  27 in total

Review 1.  Rheumatology: 7. Basics of therapy.

Authors:  S H Huang
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

Review 2.  Pharmaco-epidemiological perspectives.

Authors:  U Bergman
Journal:  Pharm Weekbl Sci       Date:  1989-10-20

Review 3.  Non-steroidal anti-inflammatory drug-induced gastropathy. Mechanisms and management.

Authors:  S Szabo; W F Spill; K D Rainsford
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 4.  The treatment of osteoarthritis.

Authors:  A C Jones; M Doherty
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

Review 5.  Histamine H2-receptor antagonists in peptic ulcer disease. Evidence for a prophylactic use.

Authors:  J Nash; L Lambert; M Deakin
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

Review 6.  Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Authors:  John L Wallace
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

Review 7.  Misoprostol: pharmacoeconomics of its use as prophylaxis against gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs.

Authors:  L B Barradell; R Whittington; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 8.  Pharmacoeconomics of chronic nonmalignant pain.

Authors:  M J Zagari; P D Mazonson; W C Longton
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

9.  Nabumetone. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases.

Authors:  H A Friedel; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 10.  From peptic ulcer disease to NSAID gastropathy. An evolving nosology.

Authors:  S H Roth
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.